Aadi Bioscience, Inc. (NASDAQ:AADI) CEO Sells $13,371.50 in Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon sold 5,690 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $2.35, for a total value of $13,371.50. Following the sale, the chief executive officer now owns 33,429 shares of the company’s stock, valued at $78,558.15. This represents a 14.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aadi Bioscience Stock Performance

Shares of AADI stock opened at $2.30 on Tuesday. Aadi Bioscience, Inc. has a one year low of $1.21 and a one year high of $3.81. The company’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $2.37. The stock has a market capitalization of $56.80 million, a price-to-earnings ratio of -1.01 and a beta of 0.64.

Hedge Funds Weigh In On Aadi Bioscience

Several large investors have recently modified their holdings of AADI. XTX Topco Ltd bought a new position in shares of Aadi Bioscience during the third quarter worth about $32,000. Two Sigma Advisers LP lifted its position in shares of Aadi Bioscience by 95.2% during the fourth quarter. Two Sigma Advisers LP now owns 61,686 shares of the company’s stock worth $195,000 after purchasing an additional 30,086 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Aadi Bioscience by 305.2% during the fourth quarter. Two Sigma Investments LP now owns 68,555 shares of the company’s stock worth $216,000 after purchasing an additional 51,638 shares during the last quarter. Northern Trust Corp lifted its position in shares of Aadi Bioscience by 33.1% during the fourth quarter. Northern Trust Corp now owns 91,151 shares of the company’s stock worth $288,000 after purchasing an additional 22,677 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Aadi Bioscience by 23.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company’s stock worth $364,000 after purchasing an additional 22,100 shares during the last quarter. Institutional investors own 52.08% of the company’s stock.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.